Ketamine Metabolite (2R,6R)‑Hydroxynorketamine Interacts with μ and κ Opioid Receptors

• Published in: ACS chemical neuroscience Vol. 12; no. 9; pp. 1487 - 1497
• Main Authors: Joseph, Thomas T, Bu, Weiming, Lin, Wenzhen, Zoubak, Lioudmila, Yeliseev, Alexei, Liu, Renyu, Eckenhoff, Roderic G, Brannigan, Grace
• Format: Journal Article
• Language: English
• Published: United States American Chemical Society 05.05.2021
• Subjects: opioid receptors; free energy perturbation; (2R,6R)-hydroxynorketamine; Ketamine; molecular dynamics; norketamine
• ISSN: 1948-7193; 1948-7193
• DOI: 10.1021/acschemneuro.0c00741

Ketamine is an anesthetic, analgesic, and antidepressant whose secondary metabolite (2R,6R)-hydroxynorketamine (HNK) has N-methyl-d-aspartate-receptor-independent antidepressant activity in a rodent model. In humans, naltrexone attenuates its antidepressant effect, consistent with opioid pathway involvement. No detailed biophysical description is available of opioid receptor binding of ketamine or its metabolites. Using molecular dynamics simulations with free energy perturbation, we characterize the binding site and affinities of ketamine and metabolites in μ and κ opioid receptors, finding a profound effect of the protonation state. G-protein recruitment assays show that HNK is an inverse agonist, attenuated by naltrexone, in these receptors with IC50 values congruous with our simulations. Overall, our findings are consistent with opioid pathway involvement in ketamine function.